-
MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer
Monday, July 26, 2021 - 9:36am | 195Read More...MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma skin cancers is being conducted at the Soroka Medical Center in Israel. ...
-
Sanofi - Regeneron's Immunotherapy Scores European Approval For Skin And Lung Cancer Settings
Friday, June 25, 2021 - 8:51am | 247Read More...The European Commission (EC) has approved Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo (cemiplimab) for two additional indications - basal cell carcinoma (BCC) and non-small cell lung cancer with over 50% PD-L1 expression. BCC (...
-
Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer
Wednesday, February 10, 2021 - 6:24am | 244Read More...Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) immunotherapy Libtayo (cemiplimab-rwlc) has scored approval from the FDA for the treatment of advanced basal cell carcinoma (BCC), the most common type of skin cancer in the U.S. The...
-
CureVac Expands Early-Stage Study Evaluating CV8102 In Skin Cancer
Thursday, February 4, 2021 - 12:09pm | 333Read More...CureVac N.V. (NASDAQ: CVAC) has expanded its ongoing Phase 1 study with its lead RNA-based cancer drug candidate, CV8102, intending to confirm safety, tolerability, and efficacy of CV8102 in patients with advanced melanoma at 600µg, the selected dose to be...
-
Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market
Wednesday, May 20, 2020 - 8:33am | 1382Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Since its establishment in 2014 by founding company Fortress Biotech, Inc. (NASDAQ: FBIO), biopharmaceutical company Checkpoint...
-
Biofrontera Celebrates Successful IPO, Prepares For US Expansion
Friday, April 6, 2018 - 11:54am | 821Read More...Biofrontera AG ADR (NASDAQ: BFRA) is trading 53 percent above its Feb. 14 initial public offering price, justifying the company's pursuit of a U.S. market debut. The German company added a Nasdaq listing alongside a presence on the Frankfurt Stock Exchange to increase not only capital, but also...
